Table 1.

Overexpression on the 20K cDNA Array of Targets and Corresponding P Values in CaP Metastases Compared with Localized Disease and Benign Prostatic Hyperplasia.

Target	ANOVA	Post hoc (Scheffé)
		Benign Prostate Tissue vs CaP Metastases	Localized CaP vs CaP Metastases
BAP1	.094	NS	NS
BRCA1	.156	NS	NS
PSG2	.002	<.01	<.05
MPV17	.002	<.01	<.05
Stau2	.001	.01	<.01
Mark3	.025	NS	<.05
MCM3	.019	NS	<.05
PMSCL2	.010	NS	.01
MAPK3	.109	NS	NS
RHAMM	.004	<.05	.01

For statistical analysis, a multifactorial ANOVA was performed.

Group factors: expression in benign prostate tissue samples, localized CaP, and CaP metastases. Significance was approved with post hoc tests (Scheffé). On cDNA level, no significant differences between localized CaP and benign prostate tissue were found.

NS indicates not significant.